Improving Clinical Outcomes and Patient Satisfaction in Ulcerative Colitis: Positioning of Therapies in the Treatment of UC

Join us for a livestream event on
Twitter, Facebook, or YouTube! 


Saturday, January 30, 2021
10:30 AM – 11:30 AM EST



Aline Charabaty, MD, AGAF
Johns Hopkins School of Medicine
Clinical Director, GI Division
Director, IBD Center
John Hopkins – Sibley Memorial Hospital
Washington, District of Columbia


Millie Long MD, MPH
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina


Miguel Regueiro, MD
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, DDS
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, Ohio


Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), reduces patients’ quality of life and is associated with substantial medical, financial, and social burdens. More than 3 million people in the US and Europe are estimated to have IBD. Despite recent advances in IBD therapies, clinicians are still faced with challenges in treating and managing their patients with UC. Clinicians must choose from a vast array of agents in a variety of drug classes with different mechanisms of action, including agents that are newly available or under clinical investigation. In view of this expansion of therapeutic options, it is crucial for clinicians to remain current regarding all potential treatment strategies to ensure optimal patient outcomes. The individualized needs of specific patient populations, including patients with complex IBD, will be discussed. Additional focus will be placed on providing multidisciplinary and patient-centered approaches to care. Overall, this initiative will aim to overcome existing barriers to achieving treatment goals for patients with IBD.


This program is intended for gastroenterologists, gastroenterologists in training, surgeons, subspecialists including dieticians and psychologists, nurse practitioners, physician assistants, nurses, and other healthcare team members involved in or interested in the care of patients with IBD.


Upon completion of this educational activity, participants should be able to:

  • Apply safety and efficacy data from clinical trials and real-world studies of new and emerging agents to achieve an individualized, patient-centered approach to UC management
  • Interpret the updated UC guidelines to improve treatment decision making and care of patients
  • Evaluate potential approaches for positioning new and emerging therapies for UC
  • Describe clinical situations in which novel therapies may be advantageous for patients with complex IBD


There is no registration fee for participating in this activity. To register, click the registration buttons on this page or call Integrity Continuing Education, Inc. at 1-855-835-4004.


Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Aline Charabaty, MD, AGAF
Consulting Fees: AbbVie, Janssen, Takeda
Speakers’ Bureaus: AbbVie, Takeda

Millie Long MD, MPH
Consulting Fees: AbbVie, Gilead, Janssen, Pfizer Inc., Prometheus, Takeda, Target Pharmasolutions
Contracted Research: Pfizer Inc., Takeda

Miguel Regueiro, MD
Consulting Fees: AbbVie, Celgene, Genentech, Gilead, Janssen, Pfizer Inc., Takeda, UCB
Contracted Research: AbbVie, Janssen, Pfizer Inc., Takeda

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the view of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.


Provided by Integrity Continuing Education, Inc.

Supported by independent educational grants from AbbVie Inc., Pfizer, Inc., and Takeda Pharmaceuticals U.S.A., Inc.




On the day of the program, you may access the event by going to any of the following links:


There are no fees for participating and receiving CME credit for this activity. For your participation you will be able to receive a maximum of 1.25 AMA PRA Category 1 CME credit(s)TM. To do so, you must participate in the virtual live stream activity and complete the posttest and evaluation following the event. A statement of credit will be issued only upon submission of a completed activity evaluation form.